Black Diamond Therapeutics filings document financial results, clinical-program disclosures and governance matters for a Nasdaq-listed clinical-stage oncology company. Recent Form 8-K reports furnish quarterly and annual operating results and corporate updates tied to silevertinib, the company’s EGFR MasterKey inhibitor program for EGFR-mutant NSCLC and glioblastoma, along with liquidity and capital-expenditure commentary.
Proxy materials disclose annual meeting matters, including board-class elections, auditor ratification, advisory executive-compensation votes and the preferred frequency of future compensation votes. The filings also identify the company’s registered common stock, par value and Nasdaq Global Select Market listing under the BDTX symbol.
Black Diamond Therapeutics reported that a non-employee director received 5,208 shares of common stock as compensation for annual board service.
The shares were issued on December 12, 2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to take stock instead of cash fees.
The award was valued at $2.76 per share, based on the closing market price on December 11, 2025. Following this grant, the director beneficially owns 86,649 shares directly and has additional indirect interests in shares held by investment funds affiliated with New Enterprise Associates, while disclaiming beneficial ownership of portions in which there is no pecuniary interest.
Black Diamond Therapeutics reported that one of its non-employee directors acquired 4,665 shares of the company’s common stock on December 12, 2025, as reflected in a Form 4 insider trading report.
The shares were issued under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, after the director elected to receive stock instead of cash for annual board service. The value was based on the $2.76 closing market price on December 11, 2025, and the director now beneficially owns 31,027 shares held directly.
Black Diamond Therapeutics filed a shelf registration on Form S-3 to offer, from time to time, up to $500,000,000 of common stock, preferred stock, debt securities, warrants, and/or units. The filing also includes a sales agreement prospectus for an at-the-market program of up to $150,000,000 in common stock under an Open Market Sale AgreementSM with Jefferies LLC, which is part of the $500,000,000 shelf.
Under Rule 415(a)(6), the filing carries forward $400,005,680.55 of unsold securities from a prior shelf (File No. 333-268341); that prior offering will be deemed terminated upon effectiveness of this registration. The company’s common stock trades on Nasdaq as BDTX, and 56,943,413 shares were outstanding as of September 30, 2025. Net proceeds from any future sales are intended for general corporate purposes, including R&D, clinical development, working capital, and capital expenditures.
Black Diamond Therapeutics (BDTX) reported Q3 2025 results showing a net loss of $8,498, while year-to-date net income reached $37,483 on the back of $70,000 in license revenue recognized from its March agreement with Servier for BDTX-4933. Operating expenses declined, with R&D at $7,437 and G&A at $3,541 in Q3.
Cash, cash equivalents and investments totaled about $135.5 million as of September 30, 2025, and management estimates funding into the fourth quarter of 2027. The balance sheet strengthened: total stockholders’ equity rose to $126,152 from $83,285 at year-end 2024, while current liabilities decreased to $15,545. Shares outstanding were 56,974,913 as of October 30, 2025.
The Servier deal included a $70.0 million upfront payment and eligibility for up to $710.0 million in development and commercial milestones, plus tiered royalties on global net sales. Lead program silevertinib advanced in Phase 2, with initial frontline cohort results targeted for Q4 2025.
Black Diamond Therapeutics (BDTX) furnished an 8-K announcing financial results for the three and nine months ended September 30, 2025. The company issued a press release with the details, which is included as Exhibit 99.1. The information was furnished, not filed, under Item 2.02.
Director Behbahani Ali received 4,291 shares of Black Diamond Therapeutics common stock on 09/19/2025 under the companys Fifth Amended and Restated Non-Employee Director Compensation Policy by electing stock in lieu of cash. The report shows a per-share price of $3.35 based on the closing market price on 09/18/2025. After the issuance, the Reporting Persons direct beneficial ownership is reported as 81,441 shares and indirect ownership is reported as 4,448,757 shares through NEA 16, with a disclaimer that the Reporting Person disclaims beneficial ownership of portions where no pecuniary interest exists. The Form 4 discloses the reporting relationship as a director and that the transaction code is an acquisition for director compensation.
Raman Prakash, a non-employee director of Black Diamond Therapeutics, Inc. (BDTX), elected to receive 3,843 shares of the issuer's common stock in lieu of cash for annual director compensation. The shares were issued on 09/19/2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy. After the issuance, the reporting person beneficially owned 26,362 shares. The reported per-share price of $3.35 reflects the closing market price on 09/18/2025. The Form 4 was signed by an attorney-in-fact on 09/22/2025.